Tempus AI (NASDAQ:TEM) Director David Epstein Sells 370 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $43.40, for a total value of $16,058.00. Following the transaction, the director owned 31,094 shares in the company, valued at $1,349,479.60. This trade represents a 1.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 0.7%

NASDAQ TEM opened at $46.70 on Thursday. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32. The company has a 50-day moving average of $51.40 and a 200-day moving average of $52.12. The company has a market cap of $8.39 billion, a P/E ratio of -32.43 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm’s revenue was up 21.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) earnings per share. As a group, equities analysts predict that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Wall Street Analyst Weigh In

TEM has been the subject of a number of research reports. Wolfe Research started coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Freedom Capital raised Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Lake Street Capital cut Tempus AI to a “hold” rating in a research note on Monday, July 20th. BTIG Research lowered their target price on Tempus AI from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Monday. Finally, TD Cowen reiterated a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Nine research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Tempus AI currently has an average rating of “Hold” and an average price target of $64.92.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TEM. Vanguard Group Inc. grew its stake in Tempus AI by 8.7% in the fourth quarter. Vanguard Group Inc. now owns 10,258,621 shares of the company’s stock worth $605,772,000 after purchasing an additional 817,014 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Tempus AI by 5.3% in the 4th quarter. ARK Investment Management LLC now owns 7,557,583 shares of the company’s stock worth $446,275,000 after acquiring an additional 381,816 shares in the last quarter. GC Wealth Management RIA LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at approximately $399,267,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares in the last quarter. Finally, Amova Asset Management Americas Inc. lifted its stake in Tempus AI by 23.4% during the first quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after purchasing an additional 821,490 shares during the last quarter. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.